Collectively, these results indicate that combination of let-7b repletion with paclitaxel or gemcitabine greatly compromises the migratory ability and invasiveness of KRAS mutant tumor cells and reverts the EMT phenotype. This evidence concerns the gene KRAS and neoplasm.